EUCTR2022-002965-13-NL进行中（未招募）1 期
A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant with a diagnosis of narcolepsy who has completed a controlled study with TAK-861 (including participants diagnosed with NT1 or NT2) and for whom the investigator has no clinical objection to their enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 135
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1. Participant has a moderate or severe ongoing treatment emergent adverse event (TEAE) related to the study drug from the parent study or discontinued because of TEAEs in the parent study.
- •2. Participant has a positive urine screen for drugs of abuse (findings confirmed) and/or positive alcohol test during any visit in their prior TAK-861 study, or during the screening period for participants with a dosing gap.
- •3. Participant has a risk of suicide according to endorsement of item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) on any visit in the parent TAK-861 study, or has positive answers on item 4 or 5 on the Screening/Baseline C-SSRS Lifetime (based on the past year) during the screening assessment for participants with a dosing gap.
- •4. Participant has alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN) at multiple visits in the parent study and the findings are of clinical significance, per investigator or sponsor opinion, or ALT/AST >1.5 times ULN during the screening period for participants with a dosing gap.
- •5. Participant has a current medical disorder, other than narcolepsy with or without cataplexy, associated with excessive daytime sleepiness (EDS).
- •6. Participant has current active major depressive episode (MDE) or has had an active MDE in the past 6 months.
- •7. Participant has developed (within the last 6 months) gastrointestinal disease that is expected to influence the absorption of drugs (i.e., a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention).
- •8. Participant has epilepsy or history of seizure.
- •9. Participant has any other medical condition, such as anxiety, depression, heart disease, or significant hepatic, pulmonary, or renal disease, that requires them to take excluded medications.
- •10. Participant has a history of cerebral ischemia, transient ischemic attack (<5 years ago), or cerebral hemorrhage.
- •11. Participant has a history of myocardial infarction, clinically significant coronary artery disease, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure.
- •12. Participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment, or basal cell skin cancer.
研究者
相似试验
招募中
2 期
A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia ConditionsNL-OMON53942Takeda Development Center Americas, Inc.2
进行中（未招募）
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)MedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002965-13-FITakeda Development Center Americas, Inc.160
进行中（未招募）
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)MedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002965-13-SETakeda Development Center Americas, Inc.160
进行中（未招募）
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)MedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002965-13-FRTakeda Development Center Americas, Inc.160
招募中
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy(Type 2)MedDRA version: 20.0Level: PTClassification code: 10028713Term: Narcolepsy Class: 100000004852CTIS2023-508462-15-00Takeda Development Center Americas Inc.165